Osimertinib is a third-generation EGFR tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Sold under the brand name Tagrisso by AstraZeneca, it has become one of the most important targeted cancer therapies in the world.
At CBMeds (Curiance Biotech), we help patients, oncologists, and healthcare teams across 175 countries access Osimertinib legally, safely, and with full prescription compliance — often at a fraction of the brand price. Based in India, our ISO-certified team manages everything from sourcing to doorstep delivery in approximately 15–20 days.
| Generic name | Osimertinib |
| Brand name | Tagrisso (AstraZeneca) |
| Available doses | 40 mg, 80 mg tablets |
| Ships to | 175+ countries |
| Delivery time | 15–20 days |
| Prescription required | Yes — mandatory |
What is Osimertinib?
Osimertinib is a targeted cancer medicine that works by blocking specific mutated forms of the EGFR (epidermal growth factor receptor) protein that drive the growth of certain lung cancers. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, Osimertinib is a precision therapy — it targets only cancer cells carrying EGFR mutations, causing fewer side effects and better outcomes for eligible patients.
It was originally developed for patients whose tumours had developed resistance to earlier EGFR inhibitors (such as Erlotinib or Gefitinib) due to the T790M mutation. However, the landmark FLAURA clinical trial showed Osimertinib was also significantly more effective as a first-line treatment for EGFR-mutated NSCLC than older drugs.
Today, Osimertinib is approved by the US FDA, the European Medicines Agency (EMA), and regulators in India and across the world for:
- First-line treatment of EGFR exon 19 deletion or exon 21 L858R mutation-positive metastatic NSCLC
- Treatment of T790M mutation-positive NSCLC in patients who progressed on prior EGFR therapy
- Adjuvant (post-surgery) treatment in patients with EGFR exon 19 deletions or exon 21 L858R mutations
Osimertinib is taken orally once daily as a 40 mg or 80 mg tablet. It can cross the blood-brain barrier, making it effective against lung cancer that has spread to the brain — a major advantage over older targeted therapies.
Understanding EGFR Mutations
EGFR (Epidermal Growth Factor Receptor) is a protein on the surface of cells. In some patients with non-small cell lung cancer, the EGFR gene is mutated, causing the protein to become permanently switched on — driving uncontrolled cancer cell growth. These are called EGFR-mutant or EGFR-positive lung cancers.
Approximately 10–15% of NSCLC patients in Western countries and 30–50% of Asian NSCLC patients carry EGFR mutations. The most common are exon 19 deletions and the exon 21 L858R mutation — both make the cancer highly sensitive to Osimertinib.
| EGFR Mutation | Frequency | Osimertinib Response |
|---|---|---|
| Exon 19 deletion | ~45% of EGFR+ cases | Highly responsive — first-line use |
| Exon 21 L858R | ~40% of EGFR+ cases | Highly responsive — first-line use |
| T790M (resistance mutation) | ~50% on prior EGFR therapy | Osimertinib approved specifically for this |
| Exon 20 insertion | ~5–10% | Generally not responsive |
Your oncologist will order an EGFR mutation test (tissue biopsy or liquid biopsy) to confirm whether Osimertinib is right for you. CBMeds only supplies Osimertinib with a valid prescription from a licensed oncologist.
Osimertinib vs Tagrisso — What is the Difference?
Tagrisso is the brand name for Osimertinib made by AstraZeneca. The active ingredient in both is identical: Osimertinib mesylate. Generic versions contain the same active ingredient, in the same dose, with the same therapeutic effect — manufactured by companies that comply with WHO Good Manufacturing Practice (GMP) standards.
The key difference is cost. Brand Tagrisso can cost USD 7,000–15,000 per month in Western markets. Generic Osimertinib through CBMeds is significantly more affordable, making it accessible to patients worldwide who cannot access or afford the brand medicine locally.
| Brand Tagrisso | Generic Osimertinib (CBMeds) | |
|---|---|---|
| Active ingredient | Osimertinib mesylate | Osimertinib mesylate |
| Doses available | 40 mg, 80 mg | 40 mg, 80 mg |
| Manufacturer | AstraZeneca | WHO-GMP approved manufacturers |
| Therapeutic effect | — | Identical |
| Availability | Limited countries | 175 countries via CBMeds |
| Prescription required | Yes | Yes — mandatory |
How to Access Osimertinib Through CBMeds
CBMeds operates under the Named Patient Medicine (NPM) framework — a legal international pathway that allows patients to access medicines not commercially available or affordable in their country, with a valid prescription from their treating physician.
Step 1 — Send us your inquiry Contact CBMeds via WhatsApp, email, or our inquiry form. Tell us the medicine, dosage, and your country. Our team responds within 2 hours.
Step 2 — Share your prescription Upload a valid prescription from your licensed oncologist. We cannot process orders without a doctor’s prescription — this is a legal and safety requirement.
Step 3 — We confirm availability and price Our sourcing team confirms availability of your Osimertinib dose, provides a transparent quote including shipping, and explains the regulatory pathway for your country.
Step 4 — Payment and documentation Once you agree, we prepare all required export documentation including compliance paperwork for your country’s health authority if needed.
Step 5 — Dispatch and delivery Your medicine is packed securely and shipped via trusted international courier. Average delivery time is 15–20 days. We share tracking information throughout.
Our team communicates in 13 languages: English, Hindi, Arabic, French, German, Spanish, Portuguese, Dutch, Romanian, Urdu, Afrikaans, Croatian, and Italian.
Why Patients and Oncologists Choose CBMeds
ISO Certified Quality Every medicine we supply comes from WHO-GMP compliant manufacturers. Our ISO certification ensures the highest quality standards throughout the supply chain.
Registered Pharmaceutical Distributor We are registered with the Dutch Ministry of Health, The Hague, as an Independent Intermediary for Medicines (Registration No. 6730 BEM) and as a Pharmaceutical Distributor (Registration No. 16258 G).
175 Countries Served From India to New Zealand, the USA to South Africa — we have successfully delivered medicines to patients in 175 countries, navigating local regulations for each.
24/7 Patient Support Our dedicated patient support team is available round the clock via WhatsApp, phone, and email. You have a personal contact throughout your entire journey.
“The team at cbmeds.in has been exceptional in supporting my patients. Their experts consistently provide prompt responses and serve as a valuable source of information. In the United States, there is no other entity capable of providing access to unapproved medicines for my patients, but cbmeds.in fills that crucial gap.” — Professor Neil A. Shneider, MD, Director of the Eleanor and Lou Gehrig ALS-Center, USA
Osimertinib Dosage
Osimertinib is prescribed by oncologists based on individual patient assessment. Standard doses are:
| Dose | Indication |
|---|---|
| 40 mg once daily | Adjuvant treatment post-surgery; some resistance cases as directed by oncologist |
| 80 mg once daily | First-line and second-line treatment of advanced or metastatic EGFR-mutated NSCLC |
Important: Dosage decisions must always be made by your treating oncologist based on your specific diagnosis, mutation profile, and overall health. CBMeds supplies the prescribed dose as specified in your doctor’s prescription — we do not recommend or change dosages.
Common Side Effects
Like all cancer medicines, Osimertinib can cause side effects. Most are manageable and your oncologist will monitor you during treatment. Commonly reported side effects include:
- Diarrhoea (most common — usually mild to moderate)
- Skin rash or acne-like rash
- Dry skin and nail changes
- Mouth sores (stomatitis)
- Decreased appetite and fatigue
- Cough and shortness of breath
Rare but serious side effects include interstitial lung disease (ILD), QT prolongation (a heart rhythm issue), and keratitis (eye inflammation). If you experience sudden worsening of breathing, chest pain, or vision changes, contact your oncologist immediately.
For a complete guide, see: Osimertinib Side Effects — Full Patient Guide
Is Accessing Osimertinib Through CBMeds Legal?
Yes. We operate exclusively under the Named Patient Medicine framework — a well-established legal pathway available in most countries that allows patients to receive medicines not commercially available locally, provided:
- A licensed oncologist has prescribed the medicine for the specific patient
- The request is for personal therapeutic use — not resale or commercial distribution
- The patient or their physician complies with their country’s import regulations
CBMeds has seven years of regulatory expertise. Our General Counsel, Kriti Kapoor, and our regulatory team ensure every order is fully compliant with applicable laws.
We are committed to the Ethical Principles of the World Medical Association and support the United Nations 2030 Sustainable Development Goals related to Health and Equality.
Want to verify legality for your specific country? Visit our Country Regulations page or contact our team directly. We will confirm the specific legal pathway for your country before you place any order.
Frequently Asked Questions About Osimertinib
Is Osimertinib available in India? Yes. Generic Osimertinib is available in India. CBMeds can supply it legally with a valid oncologist prescription and ship it to patients in 175 countries worldwide.
What is the price of Osimertinib in India? Generic Osimertinib is significantly more affordable than brand Tagrisso. Contact CBMeds for an exact, transparent quote based on your dose, quantity, and country. There are no hidden charges.
Can I get Osimertinib without a prescription? No. CBMeds only supplies Osimertinib with a valid prescription from a licensed oncologist. This is a legal requirement and a patient safety measure we strictly enforce.
How long does delivery take? On average, the process from inquiry to doorstep delivery takes 15–20 days. This includes sourcing, documentation, export compliance, and international shipping.
Which countries does CBMeds ship Osimertinib to? We ship to 175 countries including the USA, UK, UAE, South Africa, Nigeria, Kenya, Philippines, Australia, and all EU member states, among many others. Contact us to confirm your country.
Is generic Osimertinib as effective as Tagrisso? Yes. Generic Osimertinib contains the identical active ingredient (Osimertinib mesylate) in the same dose, manufactured by WHO-GMP compliant facilities. It is therapeutically equivalent to Tagrisso.
Do I need to send my original prescription? A digital copy (PDF or clear photograph) is usually sufficient to begin the process. Some countries require original documents for customs clearance — our team will inform you if this applies to your country.
Can my doctor contact CBMeds directly? Absolutely. Many oncologists contact us directly on behalf of their patients. We have dedicated support for healthcare professionals and can liaise directly with your treating physician.
What if Osimertinib stops working? Osimertinib resistance can develop over time. CBMeds also has access to other oncology medicines used in subsequent treatment lines. Speak to your oncologist and contact us for availability of alternative therapies.
Is CBMeds a legitimate pharmacy? Yes. Curiance Biotech (CBMeds) is ISO certified, registered with the Dutch Ministry of Health (No. 6730 BEM and 16258 G), and has operated for over seven years, serving patients in 175 countries.
Request Osimertinib Availability
If you or your patient needs Osimertinib and are struggling to access it locally or affordably, contact CBMeds today. Our team responds within 2 hours.
